Form 8-K - Current report:
SEC Accession No. 0001171843-21-008117
Filing Date
2021-11-22
Accepted
2021-11-22 07:03:04
Documents
12
Period of Report
2021-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_111921.htm   iXBRL 8-K 45163
  Complete submission text file 0001171843-21-008117.txt   223443

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bcrx-20211119.xsd EX-101.SCH 3040
3 XBRL LABEL FILE bcrx-20211119_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE bcrx-20211119_pre.xml EX-101.PRE 22369
5 EXTRACTED XBRL INSTANCE DOCUMENT f8k_111921_htm.xml XML 3582
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 211430137
SIC: 2836 Biological Products, (No Diagnostic Substances)